Table 3.
Patient characteristics
|
|
|
irAE
|
|
|||||||
|
Overall
|
Yes
|
No
|
P
value
|
|||||||
|
n
|
Median
|
(Q1, Q3)
|
n
|
Median
|
(Q1, Q3)
|
n
|
Median
|
(Q1, Q3)
|
|
|
| Number of cycles of immunotherapy | 277 | 5 | (2, 12) | 82 | 8.0 | (3.0, 19.0) | 195 | 4.0 | (2.0, 9.0) | 0.0011 |
| LDH | 55 | 243 | (171, 290) | 25 | 190 | (163, 259) | 30 | 253 | (186, 383) | 0.0376 |
| Progression free survival (mo) | 118 | 3.9 | (1.9, 7.4) | 27 | 5.8 | (2.7, 13.0) | 91 | 3.0 | (1.7, 6.8) | 0.0204 |
| Overall survival (mo) | 288 | 11.5 | (2.9, 19.4) | 89 | 17.1 | (8.4, 23.5) | 199 | 7.2 | (2.1, 15.3) | < 0.0001 |
irAE: Immune-related adverse events.